346691-23-4

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-AMINO-6-FLUORO-3-NITROBENZOATE is used as an intermediate in the synthesis of various drugs due to its unique chemical structure, which allows for the creation of a wide range of pharmaceutical compounds.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 2-AMINO-6-FLUORO-3-NITROBENZOATE serves as an intermediate, contributing to the development of new agrochemical products that can enhance crop protection and management.
Used in Research and Development:
METHYL 2-AMINO-6-FLUORO-3-NITROBENZOATE is utilized as a reagent in organic synthesis within research and development applications, facilitating the exploration of new chemical reactions and the creation of novel chemical entities.

Upstream product

• 84832-01-9 methyl 2,6-difluoro-3-nitrobenzoate 
• 13671-00-6 methyl 2,6-difluorobenzoate 

Downstream Products

• 1193789-18-2 phenylmethyl 2-amino-3-nitro-6-[(phenylmethyl)oxy]benzoate 
• 1193789-66-0 methyl 2-amino-6-(methylamino)-3-nitrobenzoate 
• 1370000-21-7 C₁₈H₁₈FN₃ 
• 1370000-22-8 C₁₉H₂₀FN₃ 
• 1370000-26-2 C₁₈H₁₈FN₃O 
• 1370000-25-1 C₂₁H₂₄FN₃ 
• 1370000-28-4 C₁₅H₁₁FN₂O₂ 
• 1370000-29-5 C₁₄H₁₁FN₂O 
• 403712-67-4 2,3-diamino-6-fluorobenzoic acid methyl ester 
• 1160682-17-6 methyl 2,3-diamino-6-methoxybenzoate 
• 1160682-75-6 methyl 2,3-diamino-5-bromo-6-(methyloxy)benzoate 
• 1160682-52-9 methyl 2-amino-5-bromo-6-(methyloxy)-3-nitrobenzoate 
• 1160683-50-0 6-hydroxy-2-phenyl-5-quinoxalinecarboxylic acid 
• 1160682-44-9 Methyl 6-(methyloxy)-2-(phenyloxy)-5-quinoxalinecarboxylate 

Relevant academic research and scientific papers

PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF

The present invention provides novel compounds which bind to cereblon, and methods of use thereof. The compounds are represented by Formulas (I) and (II), below: (I) wherein Rx is selected from (Ia), (Ib), (Ic) and (Id); (II) wherein Ry is selected from (IIa), (IIb), (IIc) and (IId).

Benzimidazole-2-piperazine compound, its pharmaceutical composition and its preparation and use

The invention relates to a benzimidazole-2-piperazine derivative and a preparing method and application of the benzimidazole-2-piperazine derivative in medicine, in particular to a novel benzimidazole-2-piperazine derivative shown in the general formula (I), a preparing method of the derivative, a pharmaceutical composition containing the derivative and application of the derivative serving as a therapeutic agent, especially serving as a poly (ADP-ribose) polymerase (PARP) inhibitor. In the general formula (I), R refers to hydrogen or halogen, G refers to carbonyl or methylene, m is 1-2, n is 1-3, and Q refers to hydrogen or C1-C4 alkyl. When X is methylene and Y is NR1 or methylene, X is NR1; R1 refers to hydrogen, C1-C6 alkyl, benzyl, COR2 or SO2R2; R2 refers to the following groups which are not substituted or groups substituted by 1-3 substituent groups, including C1-C6 alkyl, C3-C8 naphthenic base, phenyl, benzyl, naphthyl and C5-C10 aromatic heterocycle base, heterocycle in the C5-C10 aromatic heterocycle base comprises 1-3 heteroatoms selected from N, O and S, and the substituent groups are selected from the following atoms or groups of C1-C6 alkyl, C1-C6 alkoxy, halogen, amidogen, nitryl, sulfydryl, hydroxyl, cyanogroup and trifluoromethyl. The general formula (I) is shown in the specification.

2,5-diazabicyclo [2.2.1] iieptanes and method of preparation, pharmaceutical compositions thereof and its application in medicine

The present invention relates to a class of 2,5-diazabicyclo[2.2.1]heptane derivatives and a preparation thereof, pharmaceutical compositions of the 2,5-diazabicyclo[2.2.1]heptane derivatives, and medical uses of the 2,5-diazabicyclo[2.2.1]heptane derivat

A novel series of benzimidazole NR2B-selective NMDA receptor antagonists

A series of novel benzimidazoles are discussed as NR2B-selective N-methyl-d-aspartate (NMDA) receptor antagonists. High throughput screening (HTS) efforts identified a number of potent and selective NR2B antagonists such as 1. Exploration of the substituents around the core of this template identified a number of compounds with high potency for NR2B (pIC50 >7) and good selectivity against the NR2A subunit (pIC50 2+ and radioligand binding studies. These agents offer potential for the development of therapeutics for a range of nervous system disorders including chronic pain, neurodegeneration, migraine and major depression.

Prolyl Hydroxylase Inhibitors

The invention described herein relates to certain quinoxaline-5-carboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

PROLYL HYDROXYLASE INHIBITORS

The invention described herein relates to certain benzimidazol-4-ylcarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one